Head to Head Review: Oxford BioMedica (OTCMKTS:OXBDF) & Sensei Biotherapeutics (NASDAQ:SNSE)

Oxford BioMedica (OTCMKTS:OXBDF) and Sensei Biotherapeutics (NASDAQ:SNSE) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership and earnings.

Analyst Recommendations

This is a breakdown of recent recommendations for Oxford BioMedica and Sensei Biotherapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oxford BioMedica	0	0	0	0	0.00
Sensei Biotherapeutics	1	1	1	1	2.50

Sensei Biotherapeutics has a consensus price target of $55.00, indicating a potential upside of 539.53%. Given Sensei Biotherapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Sensei Biotherapeutics is more favorable than Oxford BioMedica.

Profitability

This table compares Oxford BioMedica and Sensei Biotherapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oxford BioMedica	N/A	N/A	N/A
Sensei Biotherapeutics	N/A	-76.85%	-64.86%

Earnings & Valuation

This table compares Oxford BioMedica and Sensei Biotherapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oxford BioMedica	$164.59 million	5.18	-$46.74 million	N/A	N/A
Sensei Biotherapeutics	N/A	N/A	-$30.16 million	($19.13)	-0.45

Sensei Biotherapeutics has lower revenue, but higher earnings than Oxford BioMedica.

Volatility and Risk

Oxford BioMedica has a beta of 1.12, indicating that its share price is 12% more volatile than the S&P 500. Comparatively, Sensei Biotherapeutics has a beta of 0.31, indicating that its share price is 69% less volatile than the S&P 500.

Institutional and Insider Ownership

10.5% of Sensei Biotherapeutics shares are held by institutional investors. 23.2% of Sensei Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Sensei Biotherapeutics beats Oxford BioMedica on 7 of the 11 factors compared between the two stocks.

About Oxford BioMedica

Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its s LentiVector platform technology is an advanced lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product. The Platform segment engages in bioprocessing and process development activities for third parties. The Product segment is involved in the research and development of new gene therapeutic product candidates. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, and adenoviral vectors. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.